Catalyst Pharmaceuticals
Brian Elsbernd has extensive experience in the legal and compliance field, with a focus on healthcare. Brian served as the Chief Legal and Compliance Officer at Catalyst Pharmaceuticals from December 2018, after previously holding the role of Senior Vice President Legal and Compliance from February 2016 to December 2018. Prior to their time at Catalyst Pharmaceuticals, Elsbernd worked at Mallinckrodt Pharmaceuticals as the Senior Director of Healthcare Compliance from February 2015 to February 2016, and as the Associate General Counsel - Compliance/Chief Compliance Officer from July 2013 to February 2015. Before Mallinckrodt Pharmaceuticals, they were the Chief Compliance Officer/Compliance Counsel for Imaging Solutions and Pharmaceuticals at Covidien from November 2007 to June 2013. Elsbernd also served as the Gov't Compliance Manager at Covidien/Mallinckrodt from January 2004 to November 2007. Brian began their career as an Associate/Health Care attorney at Proskauer Rose LLP from September 1997 to December 2004. Elsbernd's early work experience includes serving as an Office Manager at Anrex Home Care from 1990 to 1994.
Brian Elsbernd attended Saint Louis University School of Law from 1994 to 1997, where they received a JD degree in Law. Prior to this, they studied at the University of Illinois Urbana-Champaign from 1982 to 1987, obtaining a Bachelor of Arts (B.A.) degree in History and Mathematics.
This person is not in any offices
Catalyst Pharmaceuticals
2 followers
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.